Skip to main content
SpringerLink
Log in

Herzinsuffizienz: AT1-Rezeptor-Blocker als Ergänzung zur optimalen Standardtherapie?

  • Chapter
Der schwerkranke und multimorbide Herzpatient

  • 47 Accesses

Zusammenfassung

Die chronische Herzinsuffizienz ist eine der häufigsten Erkrankungen in den westlichen Industrieländern. Der Anteil älterer Menschen an der Gesamtpopulation nahm in den letzten Jahrzehnten deutlich zu. Da mit steigendem Lebensalter auch die Prävalenz der Herzinsuffizienz steigt, wird diese in den kommenden Jahren zu einem der wichtigsten Probleme des Gesundheitswesens werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ardaillou R (1999) Angiotensin II receptors. J Am Soc Nephrol (Suppl 11 ) 10: 30–39

    Google Scholar 

  2. Brunner-La Rocca HP, Vaddadi G, Esler MD (1999) Recent insight into therapy of congestive heart failure: a focus on ACE inhibition and angiotensin II antagonism. J Am Coll Cardiol 33: 1163–1173

    Article  Google Scholar 

  3. Cohn JN, Tognoni G for the Val-HeFT Investigators (2001) Effect of the angiotensin receptor blocker valsartan on morbidity and mortality in heart failure: the valsartan heart failure trial ( Val-HeFT ). Circulation 102: 2672

    Google Scholar 

  4. Davie AP, Dargie HJ, McMurray JJ (1999) Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure. Circulation 100: 268–273

    PubMed  CAS  Google Scholar 

  5. Blather MD, Yusuf S, Kober L et al. (2000) Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355: 1575–1581

    Google Scholar 

  6. Hellige G, Paul M, Schrader J (1998) Angiotensin-Il-Bedeutung für die Pathophysiologie and Therapie von Herz-Kreislauf-Krankheiten. Areis-Verlag, München 1998

    Google Scholar 

  7. Juillerat L, Nussberger J, Menard J et al. (1990) Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 16: 564–572

    PubMed  CAS  Google Scholar 

  8. McKee PA, Castelli WP, McNamara PM, Kannel WB (1971) The natural history of congestive heart failure: the Framingham Study. N Engl J Med 285: 1441–1446

    Article  PubMed  CAS  Google Scholar 

  9. Packer M (1987) Prolonging life in patients with congestive heart failure: the next frontier. Circulation (Suppl IV ) 75: 1–3

    Google Scholar 

  10. Packer M (1988) Survival in patients with chronic heart failure and its potential modification by drug therapy. In: Cohn JN (ed) Drug treatment of heart failure, 2nd edn. Advanced Therapeutic Communication, Secaucus, NJ, p 273

    Google Scholar 

  11. Pitt B, Segal R, Martinez FA et al. (1997) Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE ). Lancet 349: 747–752

    Google Scholar 

  12. The Acute Infarction Ramipril Efficacy Study (AIRE) (1993) Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342: 821–828

    Google Scholar 

  13. The CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316: 1429–1435

    Article  Google Scholar 

  14. The SOLVD Investigators (1991) Effect of enalapril on survival of patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325: 293–302

    Article  Google Scholar 

  15. Urata H, Kinoshita A, Misono KS, Bumpus FM Husain A (1990) Identification of a highly specific chymase as the major angiotensin II forming enzyme in the human heart. J Biol Chem 265: 22348–22357

    PubMed  CAS  Google Scholar 

  16. Weber KT, Sun Y, Katwa LC (1996) Wound healing following myocardial infarction. Clin Cardiol 19: 447–455

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Innere Medizin III (Kardiologie/Angiologie) Medizinische Klinik und Poliklinik, Universitätskliniken, Saarlandes, 66421, Homburg/Saar, Deutschland

    N. Werner

  2. Innere Medizin III, Medizinische Klinik und Poliklinik, Universitätskliniken des Saarlandes, Homburg/Saar, Deutschland

    Prof. Dr. M. Böhm

Authors
  1. N. Werner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. M. Böhm
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Herz-Kreislauf-Klinik Waldkirch, Kandelstraße 41, 79183, Waldkirch, Deutschland

    Bernhard Rauch

  2. Deutsche Gesellschaft für Prävention und Rehabilitation von Herz-Kreislauf-Erkrankungen, Friedrich-Ebert-Ring 38, 56058, Koblenz, Deutschland

    Klaus Held

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Steinkopff Verlag Darmstadt

About this chapter

Cite this chapter

Werner, N., Böhm, M. (2001). Herzinsuffizienz: AT1-Rezeptor-Blocker als Ergänzung zur optimalen Standardtherapie?. In: Rauch, B., Held, K. (eds) Der schwerkranke und multimorbide Herzpatient. Steinkopff. https://doi.org/10.1007/978-3-642-93723-1_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-93723-1_19

  • Publisher Name: Steinkopff

  • Print ISBN: 978-3-7985-1323-5

  • Online ISBN: 978-3-642-93723-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation